Previous close | 5.12 |
Open | 5.08 |
Bid | 5.00 x N/A |
Ask | 5.30 x N/A |
Day's range | 5.08 - 5.10 |
52-week range | 1.87 - 6.36 |
Volume | |
Avg. volume | 27 |
Market cap | 179.366M |
Beta (5Y monthly) | 0.84 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Company continues pioneering research on BCI-enabled system to restore mobility after spinal cord injuryEINDHOVEN, The Netherlands, Sept. 19, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), announces another successful implant of its investigational ARC-BCI™ System to restore lower limb mobility after SCI. The
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Up-LIFT Study results published in Nature Medicine De Novo application submitted to FDA to obtain clearance to market the investigational ARC-EX® System in the United States Up to EUR 52.5M in growth financing obtained from US-based Runway Growth Capital Several additional milestones achieved with the investigational ARC-BCI™ System, leveraging brain-computer inter
Grant will enable ONWARD Medical, CEA-Clinatec and .NeuroRestore to evaluate the use of the ONWARD ARC-BCI™ System to restore thought-driven movement of the hands and arms after spinal cord injury (SCI)EINDHOVEN, the Netherlands, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces a grant